• Price (EUR)359.90
  • Today's Change-5.50 / -1.51%
  • Shares traded0.00
  • 1 Year change+80.18%
  • Beta--
Data delayed at least 15 minutes, as of Dec 09 2022 07:08 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

McKesson Corporation is a diversified healthcare services provider. The Company is focused on advancing health outcomes for patients everywhere. It operates its business through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter (OTC) pharmaceutical drugs, and other healthcare-related products. Its Prescription Technology Solutions segment serves its biopharma and life sciences partners and patients. Its Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. Its International segment provides distribution and services to wholesale, institutional, and retail customers in 11 European countries and Canada.

  • Revenue in USD (TTM)272.03bn
  • Net income in USD2.06bn
  • Incorporated1994
  • Employees58.00k
  • Location
    Mckesson Corp6555 State Highway 161IRVING 75039United StatesUSA
  • Phone+1 (972) 446-4800
  • Fax+1 (302) 636-5454
  • Websitehttps://www.mckesson.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
MCK:NYQ since
Rx Savings LLCAnnounced19 Sep 202219 Sep 2022Announced10.22%875.00m
Data delayed at least 15 minutes, as of Dec 08 2022 21:10 GMT.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.